Study #2023-0108
A phase I trial of TGN-S11 in patients with Human Papillomavirus (HPV)-associated relapsed, resistant or metastatic Cancer.
MD Anderson Study Status
Enrolling
Treatment Agent
TGN-S11, Pembrolizumab
Description
This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
HPV Associated Cancers
Study phase:
Phase I
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-961-3045
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.